APAnton PozniakMD, FRCPSlidesetHIVRussian HIV Clinical Forum 2019Reduced Drug Regimes Data and Implementation - Anton Pozniak, MD, FRCPView Slideset
SlidesetHIVRussian HIV Clinical Forum 2019Integrase Inhibitors in ART Regimens in Patients with Co-Infection - A.V. Kravchenko, DMCView Slideset
EOElena Orlova-MorozovaMD, PhDSlidesetHIVRussian HIV Clinical Forum 2019Integrase Inhibitors as a Component of Comprehensive Care... - Elena Orlova-Morozova, MD, PhDView Slideset
ASAnca Streinu-CercelMD, PhDSlidesetHIVRussian HIV Clinical Forum 2019Clinical Utility of INSTI in Women - Anca Streinu-Cercel, MD, PhDView Slideset
SlidesetHIVRussian HIV Clinical Forum 2019Clinical Criteria for Choosing an ART Regimen - O.G. YurinView Slideset
AKAlina KirichenkoMDSlidesetHIVRussian HIV Clinical Forum 2019Circulating HIV-1 and LN Subtypes to Integrase Inhibitors in the Russia - Alina KirichenkoView Slideset
VideoHIVGulf HIV Clinical Forum 2019Optimal Use of INSTIs in KSA - Ghassan Wali, MD, FRCP(C)View Video
RPRoger ParedesMD, PhDVideoHIVGulf HIV Clinical Forum 2019Two Versus Three Drugs - What are the Data? - Roger Paredes, MD, PhDView Video
VideoHIVGulf HIV Clinical Forum 2019Attributes of INSTIs as a First Line Treatment Option - Sanjay Bhagani, BSc, FRCPView Video
ACAndrea CalcagnoMD, DTM&HVideoHIVGulf HIV Clinical Forum 2019Switching ARV Therapy - Clinical and Pharmacological Considerations - Andrea Calcagno, MD, DTM&HView Video
LWLaura WatersMD, FRCPVideoHIVGulf HIV Clinical Forum 2019ARV Toxicity and Their Management (Including Weight Gain) - Laura Waters, MDView Video
RPRoger ParedesMD, PhDVideoHIVGulf HIV Clinical Forum 2019Switching ARV Therapy - Clinical and Resistance Considerations - Roger Paredes, MD, PhDView Video
